ACS Medicinal Chemistry Letters
Letter
this manuscript are included in a patent application (PCT/
US2013/025341) licensed to SphynKx.
Wong, M.; Xu, G.; Wesche, H. Sphingosine kinase activity is not required
for tumor cell viability. PLoS One 2013, 8, e68328.
(15) French, K. J.; Zhuang, Y.; Maines, L. W.; Gao, P.; Wang, W.;
Beljanski, V.; Upson, J. J.; Green, C. L.; Keller, S. N.; Smith, C. D.
Pharmacology and Antitumor Activity of ABC294640, a Selective
Inhibitor of Sphingosine Kinase-2. J. Pharmacol. Exp. Ther. 2010, 333,
ACKNOWLEDGMENTS
■
The work was supported by NIH Grants R01 GM104366 and
R01 GM067958.
1
(
29−139.
16) Beljanski, V.; Knaak, C.; Smith, C. D. A novel sphingosine kinase
inhibitor induces autophagy in tumor cells. J. Pharmacol. Exp. Ther. 2010,
333, 454−64.
ABBREVIATIONS
■
(17) Antoon, J. W.; White, M. D.; Meacham, W. D.; Slaughter, E. M.;
Sph, sphingosine; S1P, sphingosine-1-phosphate; SphK, sphin-
gosine kinase
Muir, S. E.; Elliott, S.; Rhodes, L. V.; Ashe, H. B.; Wiese, T. E.; Smith, C.
D.; Burow, M. E.; Beckman, B. S. Antiestrogenic effects of the novel
sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010, 151,
5124−35.
REFERENCES
■
(18) Raje, M. R.; Knott, K.; Kharel, Y.; Bissel, P.; Lynch, K. R.; Santos,
(
1) Spiegel, S.; Milstein, S. Sphingosine-1-phosphate: signaling inside
W. L. Design, synthesis and biological activity of sphingosine kinase 2
and out. FEBS Lett. 2000, 476, 55−57.
selective inhibitors. Bioorg. Med. Chem. 2012, 20, 183−194.
(
2) Spiegel, S.;Milstien, S. Sphingosine1-phosphate, akeycellsignaling
molecule. J. Biol. Chem. 2002, 277, 25851−25854.
3) Cohen, J. A.; Barkhof, F.; Comi, G.; Hartung, H. P.; Khatri, B. O.;
(19) Knott, K.; Kharel, Y.; Raje, M. R.; Lynch, K. R.; Santos, W. L. Effect
of alkyl chain length on sphingosine kinase 2 selectivity. Bioorg. Med.
Chem. Lett. 2012, 22, 6817−6820.
(
Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G.; Tiel-
Wilck, K.; de Vera, A.; Jin, J.; Stites, T.; Wu, S.; Aradhye, S.; Kappos, L.
Oral fingolimod or intramuscular interferon for relapsing multiple
sclerosis. N. Engl. J. Med. 2010, 362, 402−15.
(20) Patwardhan, N. N.; Morris, E. A.; Kharel, Y.; Raje, M. R.; Gao, M.;
Tomsig, J. L.; Lynch, K. R.; Santos, W. L. Structure-Activity Relationship
Studies and in Vivo Activity of Guanidine-Based Sphingosine Kinase
Inhibitors: Discovery of SphK1- and SphK2-Selective Inhibitors. J. Med.
Chem. 2015, 58, 1879−99.
(
4) Kappos, L.; Radue, E. W.; O’Connor, P.; Polman, C.; Hohlfeld, R.;
Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson,
L.; Burtin, P. A placebo-controlled trial of oral fingolimod in relapsing
multiple sclerosis. N. Engl. J. Med. 2010, 362, 387−401.
5) Neubauer, H. A.; Pitson, S. M. Roles, regulation and inhibitors of
sphingosine kinase 2. FEBS J. 2013, 280, 5317−36.
6) Bigaud, M.; Guerini, D.; Billich, A.; Bassilana, F.; Brinkmann, V.
(21) Kharel, Y.; Raje, M.; Gao, M.; Gellett, A. M.; Tomsig, J. L.; Lynch,
K. R.; Santos, W. L. Sphingosine kinase type 2 inhibition elevates
circulating sphingosine 1-phosphate. Biochem. J. 2012, 447, 149−57.
(
(22)Zemann,B.;Kinzel,B.;Muller, M.;Reuschel,R.;Mechtcheriakova,
D.; Urtz, N.; Bornancin, F.; Baumruker, T.; Billich, A. Sphingosine kinase
type 2 is essential for lymphopenia induced by the immunomodulatory
drug FTY720. Blood 2006, 107, 1454−1458.
(
Second generation S1P pathway modulators: research strategies and
clinical developments. Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2014,
(23) Olivera, A.; Mizugishi, K.; Tikhonova, A.; Ciaccia, L.; Odom, S.;
1
(
841, 745−58.
Proia, R. L.; Rivera, J. The sphingosine kinase-sphingosine-1-phosphate
axis is a determinant of mast cell function and anaphylaxis. Immunity
7) Takuwa, N.; Du, W.; Kaneko, E.; Okamoto, Y.; Yoshioka, K.;
Takuwa, Y. Tumor-suppressive sphingosine-1-phosphate receptor-2
counteracting tumor-promoting sphingosine-1-phosphate receptor-1
and sphingosine kinase 1. Am. J. Cancer Res. 2011, 1, 460−481.
2
(
007, 26, 287−97.
24) Sensken, S. C.; Bode, C.; Nagarajan, M.; Peest, U.; Pabst, O.;
Graler, M. H. Redistribution of sphingosine 1-phosphate by sphingosine
(
8) Kunkel, G. T.; Maceyka, M.; Milstien, S.; S, S. Targeting the
kinase 2 contributes to lymphopenia. J. Immunol. 2010, 184, 4133−42.
sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat.
Rev. Drug Discovery 2013, 12, 688−702.
9) Zhang, Y.; Berka, V.; Song, A.; Sun, K.; Wang, W.; Zhang, W.; Ning,
C.; Li, C.; Zhang, Q.; Bogdanov, M.; Alexander, D. C.; Milburn, M. V.;
Ahmed, M. H.; Lin, H.; Idowu, M.; Zhang, J.; Kato, G. J.; Abdulmalik, O.
Y.; Zhang, W.; Dowhan, W.; Kellems, R. E.; Zhang, P.; Jin, J.; Safo, M.;
Tsai, A. L.; Juneja, H. S.; Xia, Y. Elevated sphingosine-1-phosphate
promotes sickling and sickle cell disease progression. J. Clin. Invest. 2014,
(25) Congdon, M. D.; Childress, E. S.; Patwardhan, N. N.; Gumkowski,
J.; Morris, E. A.; Kharel, Y.; Lynch, K. R.; Santos, W. L. Structure-activity
relationship studies of the lipophilic tail region of sphingosine kinase 2
inhibitors. Bioorg. Med. Chem. Lett. 2015, 25, 4956−60.
(
(26) Kharel, Y.; Mathews, T. P.; Kennedy, A. J.; Houck, J. D.;
Macdonald, T. L.; Lynch, K. R. A rapid assay for assessment of
sphingosine kinase inhibitors and substrates. Anal. Biochem. 2011, 411,
2
(
30−235.
1
(
24, 2750−61.
27) Kharel, Y.; Morris, E. A.;Congdon, M. D.;Thorpe, S. B.;Tomsig, J.
10) Takasugi, N.; Sasaki, T.; Suzuki, K.; Osawa, S.; Isshiki, H.; Hori, Y.;
L.;Santos, W. L.;Lynch, K. R.SphingosineKinase2InhibitionandBlood
Shimada, N.; Higo, T.; Yokoshima, S.; Fukuyama, T.; Lee, V. M.;
Trojanowski, J.Q.;Tomita, T.;Iwatsubo, T. BACE1activityismodulated
by cell-associated sphingosine-1-phosphate. J. Neurosci. 2011, 31, 6850−
Sphingosine 1-Phosphate Levels. J. Pharmacol. Exp. Ther. 2015, 355, 23−
3
1.
(28) Wang, Z.; Min, X.; Xiao, S. H.; Johnstone, S.; Romanow, W.;
7.
Meininger, D.; Xu, H.; Liu, J.; Dai, J.; An, S.; Thibault, S.; Walker, N.
Molecular basis of sphingosine kinase 1 substrate recognition and
catalysis. Structure 2013, 21, 798−809.
(
11) Visentin, B.; Vekich, J. A.; Sibbald, B. J.; Cavalli, A. L.; Moreno, K.
M.; Matteo, R. G.; Garland, W. A.; Lu, Y.; Yu, S.; Hall, H. S.; Kundra, V.;
Mills, G. B.; Sabbadini, R. A. Validation of an anti-sphingosine-1-
phosphate antibody as a potential therapeutic in reducing growth,
invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006,
, 225−38.
12) Santos, W. L.; Lynch, K. R. Drugging sphingosine kinases. ACS
Chem. Biol. 2015, 10, 225−33.
13) Plano, D.; Amin, S.; Sharma, A. K. Importance of sphingosine
(29) Wang, J.; Knapp, S.; Pyne, N. J.; Pyne, S.; Elkins, J. M. Crystal
Structure of Sphingosine Kinase 1 with PF-543. ACS Med. Chem. Lett.
014, 5, 1329−33.
2
9
(
(
kinase (SphK) as a target in developing cancer therapeutics and recent
developments in the synthesis of novel SphK inhibitors. J. Med. Chem.
2
(
014, 57, 5509−24.
14) Rex, K.; Jeffries, S.; Brown, M. L.; Carlson, T.; Coxon, A.; Fajardo,
F.; Frank, B.; Gustin, D.; Kamb, A.; Kassner, P. D.; Li, S.; Li, Y.;
Morgenstern, K.; Plant, M.; Quon, K.; Ruefli-Brasse, A.; Schmidt, J.;
Swearingen, E.;Walker, N.;Wang, Z.;Watson, J. E.;Wickramasinghe, D.;
F
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX